ANHUI HUAHENG BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.5 CNY | +0.49% |
|
-1.19% | -14.60% |
| Apr. 22 | Anhui Huaheng Biotechnology's Q1 Profit Jumps 7% | MT |
| Apr. 22 | Anhui Huaheng Biotechnology's 2023 Profit Jumps 40% | MT |
| Sales 2024 * | 3.19B 441M | Sales 2025 * | 4.15B 573M | Capitalization | 16.94B 2.34B |
|---|---|---|---|---|---|
| Net income 2024 * | 633M 87.36M | Net income 2025 * | 836M 115M | EV / Sales 2024 * | 5.51 x |
| Net Debt 2024 * | 664M 91.63M | Net Debt 2025 * | 312M 43.12M | EV / Sales 2025 * | 4.16 x |
| P/E ratio 2024 * |
26.8
x | P/E ratio 2025 * |
20.3
x | Employees | - |
| Yield 2024 * |
1.15% | Yield 2025 * |
1.41% | Free-Float | 56% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.49% | ||
| 1 week | -1.19% | ||
| Current month | -3.98% | ||
| 1 month | -6.69% | ||
| 3 months | +5.10% | ||
| 6 months | +13.90% | ||
| Current year | -14.60% |
1 week
99.06
109.50
1 month
99.06115.89
Current year
98.34125.81
1 year
82.21125.90
3 years
27.65133.55
5 years
23.50133.55
10 years
23.50133.55
| Managers | Title | Age | Since |
|---|---|---|---|
Geng Hua Guo
CEO | Chief Executive Officer | 60 | 05-04-12 |
Yi Fan
DFI | Director of Finance/CFO | 47 | 15-12-31 |
Xue Li Zhang
CTO | Chief Tech/Sci/R&D Officer | 43 | 13-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qi Feng Zhang
BRD | Director/Board Member | 51 | 19-07-31 |
Lin Wu
BRD | Director/Board Member | 65 | 22-06-27 |
Heng Ping Guo
FOU | Founder | 62 | 05-04-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 107.5 | +0.49% | 703,779 |
| 24-04-25 | 107 | -0.29% | 459,218 |
| 24-04-24 | 107.3 | +2.10% | 655,531 |
| 24-04-23 | 105.1 | +0.19% | 1,103,590 |
| 24-04-22 | 104.9 | -3.59% | 1,913,757 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Anhui Huaheng Biotechnology Co Ltd is a China-based company specializing in the research and development, production and sales of amino acids and other bio-based products based on alanine series products. The Company is a high-tech enterprise focusing on synthetic biotechnology and mainly engaged in the research and development, production and sales of amino acid and its derivative products. The Company's main products include alanine series products (L-alanine, DL-alanine, β-alanine), calcium D-pantothenate and α-arbutin. The Company's products are mainly used in the fields of medicine and health products, daily chemicals, food and food additives. The Company distributes its products and services within the domestic market and to overseas markets.
Sector
Food Processing
Calendar
2024-08-14
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
107.5
CNY
Average target price
135.1
CNY
Spread / Average Target
+25.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.60% | 2.34B | |
| +2.35% | 29.8B | |
| +4.50% | 21.6B | |
| +13.39% | 11.83B | |
| +12.40% | 5.15B | |
| +11.10% | 4.21B | |
| -16.49% | 3.48B | |
| -3.79% | 3.14B | |
| +4.73% | 3.11B | |
| +27.19% | 2.79B |
- Stock Market
- Equities
- 688639 Stock
